Physician profile
Charles Michael Orr
NPI 1467421164
$1,549.04
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $345 · 2021: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $450.08 | 2019-2020 | |
| Abbott Laboratories | $409.32 | 2019-2021 | |
| Philips North America LLC | $240.40 | 2019 | |
| Edwards Lifesciences Corporation | $137.43 | 2019 | |
| Asahi Intecc USA, INC. | $124.57 | 2020 | |
| Abiomed | $123.50 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.28 | 2019 | |
| Cardiovascular Systems INC. | $15.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.